Seminoma Clinical Trial
Official title:
FDG PET-CT Based Risk Adapted Radiotherapy vs Observation for Post Chemotherapy Residual Mass in Advanced Seminoma: A Prospective Randomised Controlled Trial
Testicular tumors account for 1% of all cancers in males and germ cell tumors comprise 95% of all testicular cancers. Seminomas consist of around 50% of cases. However,adequate information is not there as 60- 80% residual disease is seen even after with the standard management of chemotherapy. With the advent of functional imaging there was hope that it could aid in more accurately targeting these tumors to systematically evaluate the role of PET-CT imaging in identifying patients diagnosed with stage IIB-IIIC seminomatous germ cell tumor, with residual visible tumor post chemotherapy who would benefit with loco regional radiotherapy. The therapeutic research in Seminomashas been relatively slow and such structured studies can allow analysis of large number of patients to report on acute and late effect of treatment outcomes using CTCAE and QOL (EORTC QLQ C-30) in these cancers. We hope that we will get help in identifying thrust areas for future research through this study.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06133543 -
Robot-assisted ICG-guided Sentinel Node Biopsy in Testicular Cancer
|
N/A | |
Recruiting |
NCT05529251 -
De-escalation Study for Stage IIa/IIb < 3 cm Seminoma
|
Phase 2 | |
Completed |
NCT00705094 -
Cardiac Function and Cardiovascular Risk Profile in Testicular Cancer Patients
|
N/A | |
Active, not recruiting |
NCT03158064 -
Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors
|
Phase 2 | |
Recruiting |
NCT01887340 -
Therapeutic Strategy Guided by PET-TDM for Patients With Seminoma
|
Phase 2 | |
Active, not recruiting |
NCT01593241 -
Therapy De-escalation in Seminoma Stage IIA/B
|
Phase 2 | |
Recruiting |
NCT04876456 -
A Phase II Trial of Cabozantinib With Patients With Refractory GCTs
|
Phase 2 | |
Active, not recruiting |
NCT03937843 -
Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma
|
Phase 2 | |
Recruiting |
NCT04435756 -
A Study of miRNA 371 in Patients With Germ Cell Tumors
|
||
Active, not recruiting |
NCT02834013 -
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
|
Phase 2 | |
Recruiting |
NCT06309745 -
THERApy De-escalation for TESTicular Cancer
|
||
Recruiting |
NCT04914026 -
MicroRNA as Markers in Testicular Cancer
|
||
Active, not recruiting |
NCT02375204 -
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors
|
Phase 3 | |
Recruiting |
NCT06144736 -
PRIMETEST II - Clinical Stage II A/B Seminoma Treated With RA-RPLND
|
Phase 2 | |
Recruiting |
NCT02341989 -
Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) Versus Carboplatin in Stage I Seminomatous Testicular Cancer
|
Phase 3 |